188 related articles for article (PubMed ID: 30624466)
21. Dual effect of WIN-34B on osteogenesis and osteoclastogenesis in cytokine-induced mesenchymal stem cells and bone marrow cells.
Seo BK; Ryu HK; Park YC; Huh JE; Baek YH
J Ethnopharmacol; 2016 Dec; 193():227-236. PubMed ID: 27401292
[TBL] [Abstract][Full Text] [Related]
22. Regulation of RANKL-Induced Osteoclastogenesis by 635-nm Light-Emitting Diode Irradiation Via HSP27 in Bone Marrow-Derived Macrophages.
Lee G; Kim B; Ko Y; Park M; Kim D; Ryu KH; Jun YC; Sohn HM; Lim W
Photomed Laser Surg; 2017 Feb; 35(2):78-86. PubMed ID: 27626322
[TBL] [Abstract][Full Text] [Related]
23. FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans.
Yu H; Herbert BA; Valerio M; Yarborough L; Hsu LC; Argraves KM
Lipids Health Dis; 2015 Jul; 14():66. PubMed ID: 26138336
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of minocycline on osteoclastogenesis in mouse bone marrow cells.
Nagasawa T; Arai M; Togari A
Arch Oral Biol; 2011 Sep; 56(9):924-31. PubMed ID: 21377143
[TBL] [Abstract][Full Text] [Related]
25. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
26. Effects of ProRoot MTA, Bioaggregate, and Micromega MTA on odontoblastic differentiation in human dental pulp cells.
Chang SW; Lee SY; Kum KY; Kim EC
J Endod; 2014 Jan; 40(1):113-8. PubMed ID: 24332001
[TBL] [Abstract][Full Text] [Related]
27. Anti-osteoclastogenesis of Mineral Trioxide Aggregate through Inhibition of the Autophagic Pathway.
Cheng X; Zhu L; Zhang J; Yu J; Liu S; Lv F; Lin Y; Liu G; Peng B
J Endod; 2017 May; 43(5):766-773. PubMed ID: 28292604
[TBL] [Abstract][Full Text] [Related]
28. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors.
Strålberg F; Kassem A; Kasprzykowski F; Abrahamson M; Grubb A; Lindholm C; Lerner UH
J Leukoc Biol; 2017 May; 101(5):1233-1243. PubMed ID: 28196851
[TBL] [Abstract][Full Text] [Related]
30. Protocatechuic Acid Attenuates Osteoclastogenesis by Downregulating JNK/c-Fos/NFATc1 Signaling and Prevents Inflammatory Bone Loss in Mice.
Park SH; Kim JY; Cheon YH; Baek JM; Ahn SJ; Yoon KH; Lee MS; Oh J
Phytother Res; 2016 Apr; 30(4):604-12. PubMed ID: 26792397
[TBL] [Abstract][Full Text] [Related]
31. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
32. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
33. Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-κB signalling pathway.
Doss HM; Samarpita S; Ganesan R; Rasool M
Life Sci; 2018 Aug; 207():284-295. PubMed ID: 29908722
[TBL] [Abstract][Full Text] [Related]
34. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
[TBL] [Abstract][Full Text] [Related]
35. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
[TBL] [Abstract][Full Text] [Related]
36. Mineral trioxide aggregate (MTA) inhibits osteoclastogenesis and osteoclast activation through calcium and aluminum activities.
Rezende TMB; Ribeiro Sobrinho AP; Vieira LQ; Sousa MGDC; Kawai T
Clin Oral Investig; 2021 Apr; 25(4):1805-1814. PubMed ID: 32789653
[TBL] [Abstract][Full Text] [Related]
37. The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption.
Coon D; Gulati A; Cowan C; He J
J Endod; 2007 Apr; 33(4):432-6. PubMed ID: 17368333
[TBL] [Abstract][Full Text] [Related]
38. NF-κB pathway inhibition by anthrocyclic glycoside aloin is key event in preventing osteoclastogenesis in RAW264.7 cells.
Pengjam Y; Madhyastha H; Madhyastha R; Yamaguchi Y; Nakajima Y; Maruyama M
Phytomedicine; 2016 Apr; 23(4):417-28. PubMed ID: 27002412
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
[TBL] [Abstract][Full Text] [Related]
40. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
Park EK; Kim MS; Lee SH; Kim KH; Park JY; Kim TH; Lee IS; Woo JT; Jung JC; Shin HI; Choi JY; Kim SY
Biochem Biophys Res Commun; 2004 Dec; 325(4):1472-80. PubMed ID: 15555594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
